BioNTech is trading 4.56% lower at $84.10 in pre-market after an October 26 Phase 3 update indicated modest benefit. - DYNASTY-Breast02 met its progression-free-survival endpoint, but the companies described the benefit as modest and said available data suggest potential patient benefit may be limited. - Overall-survival data remain immature; more interstitial lung disease was reported than in prior trials. - The October 25 pumitamig update reported encouraging Phase 2 lung-cancer results; major indexes were modestly positive. Price context compares the pre-market move with the October 23 close.